
Enveda is a biotechnology company that is learning from life’s chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms—the vast majority of which have never been explored by science—creating a database of chemical biodiversity: the library of life. By growing, organizing, translating, and searching this unique library, Enveda learns from life’s evolved solutions to address today’s pressing medical needs. For more information on Enveda, visit enveda.com.

Enveda is a biotechnology company that is learning from life’s chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms—the vast majority of which have never been explored by science—creating a database of chemical biodiversity: the library of life. By growing, organizing, translating, and searching this unique library, Enveda learns from life’s evolved solutions to address today’s pressing medical needs. For more information on Enveda, visit enveda.com.
What they do: AI-driven drug discovery using natural-product/metabolomic chemistry
Founded / HQ: 2019, Boulder, Colorado
Stage / funding: Multiple rounds; announced $55M Series B (June 2024); total capital reported $230M
Team / scale: Founder & CEO: Viswa Colluru; Scientific Co‑Founder: Pieter Dorrestein; ~334 employees (reported)
| Company |
|---|
Drug discovery and development focused on natural products / metabolomics
2019
Biotechnology Research
$4.9M
Seed round reported December 16, 2020 to build a medicinal-plant database
$55M
Series B2 announced with new investors including Microsoft, The Nature Conservancy, Premji Invest and Lingotto; reported to bring total capital to $230M
“Mix of venture and strategic investors including Microsoft, The Nature Conservancy, Premji Invest, Lingotto, Kinnevik, True Ventures, FPV, Level Ventures and Jazz Venture Partners”